氟达拉滨联合减量环磷酰胺及低剂量胸腺球蛋白预处理用于再生障碍性贫血异基因造血干细胞移植的KSGCT前瞻性研究
结果显示除1例早期死亡外均获中性粒细胞植入,无重度急性GVHD,1年及3年总生存率均为96.3%,但慢性GVHD累积发生率37.7%,提示该方案安全有效但需改善慢性GVHD。
要点
- 减量环磷酰胺联合低剂量胸腺球蛋白预处理可维持植入且未增加重度急性GVHD。
- 1年及3年总生存率均为96.3%,但1年慢性GVHD累积发生率达37.7%。
- 移植后混合嵌合常见,但继发植入失败罕见。
核心结论
- 该预处理方案在成人再生障碍性贫血异基因移植中安全有效,但慢性GVHD发生率相对较高需进一步改进。
主要发现
- 除1例早期死亡外,所有患者均获得中性粒细胞植入,中位植入时间19天。
- 6例和5例患者分别在第30天和第90天检测到混合嵌合。
- 仅1例患者出现继发植入失败且为完全供者型嵌合。
- 无患者发生重度急性GVHD,1年慢性GVHD累积发生率为37.7%。
- 1年及3年总生存率均为96.3%。
关键数值与推荐
- 预处理方案:氟达拉滨120 mg/m2、环磷酰胺100 mg/kg、胸腺球蛋白2.5 mg/kg,联合或不联合2 Gy全身照射。
- 1例患者在第60天检测到高EB病毒DNA载量,1年内无患者发生EB病毒淋巴增殖性疾病。
临床怎么用
- 该减量预处理方案可用于成人再生障碍性贫血异基因移植,需关注慢性GVHD的预防和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal pre-transplant conditioning for aplastic anemia (AA) remains unclear. We performed a prospective study on allogeneic transplantation from a related or unrelated donor for adult patients with AA. We assessed whether reduced-dose cyclophosphamide (CY) could decrease toxicity while maintaining engraftment, and low-dose thymoglobulin could safely prevent graft-vs-host disease (GVHD). The pre-transplant conditioning regimen consisted of fludarabine 120 mg/m2 , CY 100 mg/kg, and thymoglobulin 2.5 mg/kg with or without 2 Gy of total body irradiation. Twenty-seven patients with a median age of 36 years were analyzed. Sixteen patients received graft from related donors. The stem cell source was bone marrow in 26 patients. All of the patients but one, who died early, achieved neutrophil engraftment at a median of 19 days. Mixed chimerism was observed in six and five patients at days 30 and 90, respectively. Only one patient experienced secondary engraftment failure with complete donor-type chimerism. None of the patients developed severe acute GVHD. The cumulative incidence of chronic GVHD was 37.7% at 1 year. The overall survival rate was 96.3% at 1 year and 3 years. A high EB virus-DNA load was detected in one patient at days 60. No one developed EBV-lymphoproliferative disorder within a year. The results suggest that the conditioning regimen in this study was safe and effective. However, relatively high incidence of chronic GVHD needs further improvement.
引用
- Kako S, Kanda Y, Onizuka M, et al. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2019. PMID: 31804748. doi:10.1002/ajh.25693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。